Merck: Keytruda As A Growth Driver

Merck (MRK) has been struggling to drive top-line growth for years, resulting in a lack of growth of its share price as well. But now, its oncology business has gotten a huge boost from a drug with a lot of potential. Growth is already picking up massively, and it is just a matter of time before it will have a significant impact on the company’s top-line as well.

In need of a growth driver

The industry Merck operates in is a competitive one, which can be seen when we look at the company’s historical top-line performance. There is a clear lack of revenue growth.


It's on us. Share your news here.

Submit your stories and articles to citybizlist today.